Journal of Clinical Oncology, 38(29), 3377-3387. American Society of Clinical Oncology Journal of Clinical Oncology, 38(29). American Society of Clinical Oncology Lugtenburg, P J, De Nully Brown, P, Van der Holt, B, D'Amore, F A, Koene, H R, De Jongh, E, Fijnheer, R, Van Esser, J W, Bohmer, L H, Pruijt, J F, Verhoef, G E, Hoogendoorn, M, Bilgin, M Y, Nijland, M, Van der Burg-De Graauw, N C, Oosterveld, M, Jie, K S G, Larsen, T S, Van der Poel, M W, Leijs, M B, Silbermann, M H, Van Marwijk Kooy, M, Beeker, A, Kersten, M J, Doorduijn, J K, Tick, L W, Brouwer, R E, Lam, K H, Burggraaff, C N, De Keizer, B, Arens, A I, De Jong, D, Hoekstra, O S & Zijlstra-Baalbergen, J M 2020, ' Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma : A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84) ', Journal of Clinical Oncology, vol. 38, no. 29, pp. 3377-3387 . https://doi.org/10.1200/JCO.19.03418 Journal of clinical oncology, 38(29), 3377-3387. American Society of Clinical Oncology Lugtenburg, P J, De Nully Brown, P, Van der Holt, B, D'Amore, F A, Koene, H R, De Jongh, E, Fijnheer, R, Van Esser, J W, Bohmer, L H, Pruijt, J F, Verhoef, G E, Hoogendoorn, M, Bilgin, M Y, Nijland, M, Van der Burg-De Graauw, N C, Oosterveld, M, Jie, K S G, Larsen, T S, Van der Poel, M W, Leijs, M B, Silbermann, M H, Van Marwijk Kooy, M, Beeker, A, Kersten, M J, Doorduijn, J K, Tick, L W, Brouwer, R E, Lam, K H, Burggraaff, C N, De Keizer, B, Arens, A I, De Jong, D, Hoekstra, O S & Zijlstra-Baalbergen, J M 2020, ' Rituximab-chop with early rituximab intensification for diffuse large b-cell lymphoma : A randomized phase iii trial of the hovon and the nordic lymphoma group (hovon-84) ', Journal of Clinical Oncology, vol. 38, no. 29, pp. 3377-3387 . https://doi.org/10.1200/JCO.19.03418 Journal of Clinical Oncology, 38, 29, pp. 3377-3387 Journal of Clinical Oncology, 38(29), 3377-3387. AMER SOC CLINICAL ONCOLOGY Journal of Clinical Oncology, 38(29):38, 3377-3387. American Society of Clinical Oncology Journal of Clinical Oncology, 38, 3377-3387 Lugtenburg, P J, de Nully Brown, P, van der Holt, B, D'Amore, F A, Koene, H R, de Jongh, E, Fijnheer, R, van Esser, J W, Böhmer, L H, Pruijt, J F, Verhoef, G E, Hoogendoorn, M, Bilgin, M Y, Nijland, M, van der Burg-de Graauw, N C, Oosterveld, M, Jie, K-S G, Larsen, T S, van der Poel, M W, Leijs, M B, Silbermann, M H, van Marwijk Kooy, M, Beker, A, Kersten, M J, Doorduijn, J K, Tick, L W, Brouwer, R E, Lam, K H, Burggraaff, C N, de Keizer, B, Arens, A I, de Jong, D, Hoekstra, O S & Zijlstra-Baalbergen, J M 2020, ' Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84) ', Journal of Clinical Oncology, vol. 38, no. 29, 38, pp. 3377-3387 . https://doi.org/10.1200/JCO.19.03418, https://doi.org/DOI: 10.1200/JCO.19.03418
Cancers, vol. 13, no. 4, pp. 672 Cancers, Vol. 13, No 4 (2021) P. 672 Cancers Volume 13 Issue 4 Cancers, 13 Janssen, J, Löwenberg, B, Manz, M, Bargetzi, M, Biemond, B, von dem Borne, P, Breems, D, Brouwer, R, Chalandon, Y, Deeren, D, Efthymiou, A, Gjertsen, B T, Graux, C, Gregor, M, Heim, D, Hess, U, Hoogendoorn, M, Jaspers, A, Jie, A, Jongen-Lavrencic, M, Klein, S, van der Klift, M, Kuball, J, van Lammeren-Venema, D, Legdeur, M C, van de Loosdrecht, A, Maertens, J, Kooy, M V M, Moors, I, Nijziel, M, van Obbergh, F, Oosterveld, M, Pabst, T, van der Poel, M, Sinnige, H, Spertini, O, Terpstra, W, Tick, L, van der Velden, W, Vekemans, M C, Vellenga, E, de Weerdt, O, Westerweel, P, Stüssi, G, van Norden, Y & Ossenkoppele, G 2021, ' Inferior outcome of addition of the aminopeptidase inhibitor tosedostat to standard intensive treatment for elderly patients with aml and high risk mds ', Cancers, vol. 13, no. 4, 672, pp. 1-11 . https://doi.org/10.3390/cancers13040672 Cancers, Vol. 13, no. 4, p. 672 [1-11] (2021) Cancers, Vol 13, Iss 672, p 672 (2021) Cancers, 13(4):672, 1-11. Multidisciplinary Digital Publishing Institute (MDPI) Janssen, Jeroen; Löwenberg, Bob; Manz, Markus; Bargetzi, Mario; Biemond, Bart; Borne, Peter von dem; Breems, Dimitri; Brouwer, Rolf; Chalandon, Yves; Deeren, Dries; Efthymiou, Anna; Gjertsen, Bjørn-Tore; Graux, Carlos; Gregor, Michael; Heim, Dominik; Hess, Urs; Hoogendoorn, Mels; Jaspers, Aurelie; Jie, Asiong; Jongen-Lavrencic, Mojca; ... (2021). Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS. Cancers, 13(4) MDPI AG 10.3390/cancers13040672 Cancers, 13, 4 Cancers, 13(4):672. Multidisciplinary Digital Publishing Institute (MDPI) Cancers, 13(4):672. MDPI AG CANCERS
Annals of Hematology Oosten, L E M, Chamuleau, M E D, Thielen, F W, de Wreede, L C, Siemes, C, Doorduijn, J K, Smeekes, O S, Kersten, M J, Hardi, L, Baars, J W, Demandt, A M P, Stevens, W B C, Nijland, M, van Imhoff, G W, Brouwer, R, Uyl-de Groot, C A, Kluin, P M, de Jong, D & Veelken, H 2018, ' Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens ', Annals of Hematology, vol. 97, no. 2, pp. 255-266 . https://doi.org/10.1007/s00277-017-3167-7 Annals of Hematology, 97(2), 255-266. Springer-Verlag Annals of Hematology, 97(2), 255-266 Annals of Hematology, 97, 2, pp. 255-266 Annals of Hematology, 97, 255-266 Annals of Hematology, 97(2), 255-266. Springer Annals of Hematology, 97(2), 255-266. Springer Verlag Annals of Hematology, 97(2), 255-266. SPRINGER Annals of hematology, 97(2), 255-266. Springer Verlag